ArticleJournal of hematology & oncology2021

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.

Guoling Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.